- For Print
- September 28, 2007
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that the Company established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium. Eisai SA/NV is owned by Eisai Europe Limited (Headquarters: London, President: Yutaka Tsuchiya).
Serving as the regional sales hub for Benelux (Belgium, Netherlands and Luxembourg), which is the sixth largest market in the EU, Eisai SA/NV will start marketing activities in all three Benelux countries hereafter with the focus on the anti-epileptic drugs Zonegran® and Inovelon®, as well as the non-opioid severe chronic pain agent Prialt®. In addition, Eisai SA/NV plans to start co-promotion of its Alzheimer's disease treatment Aricept® in Belgium and Luxembourg with its co-promotion partner.
Eisai plans further expansion of its business operations across Europe and will undertake “Independent Marketing” activities by using their own sales and marketing personnel, tailored for each county. Eisai SA/NV is the Company's ninth marketing subsidiary in Europe, and brings the total number of countries where Eisai undertake sales and marketing operations through its own distribution channels to 17, including; the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Belgium, Netherlands, and Luxembourg.
Through stable provision of Eisai's products, further enabled by the establishment of new subsidiaries and branches, Eisai is committed to increasing patient value and fulfilling the diverse needs of patients and their families throughout Europe.
|Company Name :||Eisai SA/NV|
|Establishment Date :||September 10, 2007 (Local Time)|
|Capital :||7 million Euros (approx. 1,100 million yen)|
|Location :||Brussels, Belgium|
|Operations :||Promoting the sale of pharmaceutical products|
Corporate Communications Department
Eisai Co., Ltd.